Terrence Curley, DO
Family Medicine · Philadelphia, PANPI 1700971058
Payments from drug & device makers
Across 453 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Boehringer Ingelheim$786
- Lilly USA, LLC$733
- Novo Nordisk$722
- AstraZeneca$580
- AbbVie$458
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,01399%
- Education$110%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 95 | $1,718 |
| Boehringer Ingelheim | 38 | $786 |
| Lilly USA, LLC | 41 | $733 |
| Novo Nordisk | 44 | $722 |
| AstraZeneca | 33 | $580 |
| AbbVie(2 entities) | 25 | $458 |
| Abbott | 19 | $424 |
| Merck | 33 | $422 |
| Teva Pharmaceuticals USA, Inc. | 18 | $319 |
| Novartis | 14 | $215 |
| Amgen | 9 | $159 |
| Astellas Pharma US Inc | 9 | $157 |
| Sanofi-aventis U.S. LLC | 9 | $147 |
| Pfizer | 8 | $121 |
| Johnson & Johnson | 7 | $120 |
| Bayer | 5 | $117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $111 |
| BD | 4 | $78 |
| Mannkind Corporation | 2 | $73 |
| Kowa Pharmaceuticals America, Inc. | 4 | $64 |
| Amarin Pharma, Inc. | 4 | $60 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| Lupin Inc. | 2 | $50 |
| UCB, Inc. | 2 | $50 |
| Ironwood Pharmaceuticals, Inc | 3 | $49 |
| Exact Sciences | 2 | $47 |
| Biogen | 2 | $34 |
| Verona Pharma, Inc. | 1 | $32 |
| Circassia Inc. | 2 | $30 |
| Smith+Nephew | 1 | $30 |
| Vertical Pharmaceuticals, LLC | 2 | $27 |
| Sanofi | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
How this compares
$8,083 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 119 | $91,987 |
| JanuviaSitagliptin Phosphate | 87 | $90,963 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $66,432 |
| JardianceEmpagliflozin | 47 | $60,077 |
| XareltoRivaroxaban | 45 | $32,349 |
| TrulicityDulaglutide | 12 | $27,930 |
| CreonLipase/Protease/Amylase | 12 | $24,711 |
| EntrestoSacubitril/Valsartan | 27 | $22,298 |
| FarxigaDapagliflozin Propanediol | 27 | $21,783 |
| LinzessLinaclotide | 36 | $21,127 |
| OzempicSemaglutide | 15 | $19,609 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 441 | $19,232 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $18,492 |
| MyrbetriqMirabegron | 27 | $12,819 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $10,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $1,718 | $95,069143 claims |
| PfizerEliquis | $121 | $91,987119 claims |
| MerckJanuvia | $422 | $90,96387 claims |
| Boehringer IngelheimJardiance, Tradjenta | $786 | $66,69558 claims |
| AbbVieCreon, Linzess | $458 | $45,83848 claims |
| Johnson & JohnsonXarelto | $120 | $32,34945 claims |
| Lilly USA, LLCTrulicity | $733 | $27,93012 claims |
| NovartisEntresto | $215 | $22,29827 claims |
| AstraZenecaFarxiga | $580 | $21,78327 claims |
| Novo NordiskOzempic | $722 | $19,60915 claims |
| Astellas Pharma US IncMyrbetriq | $157 | $12,81927 claims |
| Sanofi-aventis U.S. LLCLantus | $147 | $2,86727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Philadelphia
- Daniel LinPhiladelphia$392K
- Glenn RosenPhiladelphia$367K
- Christopher ChambersPhiladelphia$350K
- Deborah WittPhiladelphia$226K
- Michael AttanasioPhiladelphia$214K
- Jonah MinkPhiladelphia$145K
- Celia EzidiegwuPhiladelphia$118K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.